Novonesis A/S – Adr ((NVZMY)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Novonesis A/S – Adr (NVZMY) is conducting a clinical study titled A Randomized, Double-Blind, Placebo-Controlled Decentralized Trial to Assess the Effect and Tolerability of Limosilactobacillus Reuteri DSM 17648 Supplement in Healthy Adults Reporting Upper Gastrointestinal Discomfort. The study aims to evaluate the effectiveness of the Limosilactobacillus reuteri DSM 17648 supplement in alleviating symptoms of upper gastrointestinal discomfort, improving quality of life, and assessing its impact on gut microbiota.
The intervention being tested is a dietary supplement, Limosilactobacillus reuteri DSM 17648, which participants will take daily for eight weeks. The supplement is designed to reduce symptoms such as acid reflux and improve gastrointestinal-related quality of life.
The study employs a randomized, parallel intervention model with triple masking, involving participants, investigators, and outcomes assessors. The primary purpose is treatment, comparing the effects of the supplement against a placebo.
Key dates include the study’s start on September 1, 2025, with the latest update submitted on September 19, 2025. These dates are crucial for tracking the study’s progress and potential impact on the market.
The outcome of this study could significantly influence Novonesis A/S’s stock performance and investor sentiment, especially if the results demonstrate the supplement’s efficacy. Competitors in the dietary supplement industry may also be affected, depending on the study’s findings.
The study is currently ongoing, with further details available on the ClinicalTrials portal.